Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Operating Leases (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Operating Leases data on record, last reported at $4.0 million in Q3 2025.

  • For Q3 2025, Operating Leases changed N/A year-over-year to $4.0 million; the TTM value through Sep 2025 reached $4.0 million, changed N/A, while the annual FY2024 figure was $4.8 million, 4350.93% up from the prior year.
  • Operating Leases reached $4.0 million in Q3 2025 per CTNM's latest filing, down from $4.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $4.8 million in Q4 2024 and bottomed at $108000.0 in Q4 2023.
  • Average Operating Leases over 3 years is $2.6 million, with a median of $4.0 million recorded in 2025.
  • Peak YoY movement for Operating Leases: skyrocketed 4350.93% in 2024, then skyrocketed 3691.15% in 2025.
  • A 3-year view of Operating Leases shows it stood at $108000.0 in 2023, then surged by 4350.93% to $4.8 million in 2024, then fell by 16.46% to $4.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $4.0 million in Q3 2025, $4.3 million in Q2 2025, and $4.5 million in Q1 2025.